Delivery Order SPE2DB25D3020-SPE2DB25FWKNF
- Not listed
- The Defense Logistics Agency (DLA) awarded a $26,109.77 delivery order to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement, serves...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,303.18 on August 28, 2025, for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of August 29, 2025. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 30 tablets of DESCOVY 200-25 mg, valued at $4,596.10, with an ultimate completion date of August 13, 2025. This is a firm fixed-price contract with no set-aside designation, issued competitively to the Conshohocken, Pennsylvania-based pharmaceutical distributor. The delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime...
- The Defense Logistics Agency awarded a delivery order valued at $5,662.17 to AmerisourceBergen Drug Corp for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units. This competitively awarded, firm fixed price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which is valued at $999,999,999.00 and extends through December 2026. The pharmaceutical product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $36,331.88 to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (quantity: 30 units) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded procurement of pharmaceutical supplies for federal medical needs. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters....
- The Defense Logistics Agency awarded a $15,047.95 delivery order to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) on August 7, 2025, with an ultimate completion date of August 8, 2025. This is a firm fixed price, non-set-aside contract that leverages AmerisourceBergen's existing pharmaceutical supply infrastructure. The place of performance is the contractor's corporate office in Conshohocken, Pennsylvania. As a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) valued at $20,629.38 under a firm fixed-price contract. The award was made on September 3, 2025, with an ultimate completion date of September 4, 2025, and represents a non-set-aside competitive award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the prime contractor and will perform this delivery order from its corporate office location...
- The Defense Logistics Agency awarded a delivery order valued at $22,737.60 to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) under a firm fixed price contract. This delivery order, issued on September 4, 2025, with an ultimate completion date of September 5, 2025, represents a non-competitive set-aside award to support federal pharmaceutical procurement needs. The pharmaceutical product will be performed and distributed from AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order valued at $37,649.28 to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units. This is a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. The contract is scheduled for ultimate completion by July 30, 2025, with performance based at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $62K to AmerisourceBergen Drug Corp for DESCOVY 200-25 mg tablets (30-count units) under a firm fixed-price contract type. The award was made on September 2, 2025, with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its...
- SPE2DB25D3020Indefinite Delivery Contract
- SPE2DB25D3020-SPE2DB25FWKNFDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of DESCOVY 200-25 mg tablets in quantities of 30 units, with a contract value of $4,987.45. This competitively awarded, non-set-aside delivery order carries a firm fixed price and is scheduled for completion by September 11, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 through December 2026 that supports military healthcare programs globally. AmerisourceBergen Drug Corp is a major pharmaceutical distributor and critical vendor for federal medical procurement, serving the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company maintains an extensive portfolio of federal contract awards with DLA focused on delivering brand-name and generic pharmaceuticals, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The firm's track record demonstrates consistent capability to meet federal procurement requirements through competitive procurement processes, with delivery orders ranging substantially in value. DLA is currently planning to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards to maintain supply chain flexibility and competition among vendors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.0k | 9/10/25 |